Electric field device takes on liver tumors in early trial
NCT ID NCT03203525
First seen Jun 26, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This early-phase study tests a portable device that sends gentle electric fields to the liver, combined with chemotherapy and a targeted drug (bevacizumab), in people whose cancer has spread to the liver and stopped responding to standard treatments. The main goal is to find the safest dose and see if the combination can shrink tumors. About 38 participants will be enrolled at MD Anderson Cancer Center.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Bevacizumab (Avastin) plus chemotherapy drugs (oxaliplatin, leucovorin, fluorouracil, pegylated liposomal doxorubicin hydrochloride, temsirolimus) and the NovoTTF-100L(P) device that delivers electric fields
- What this could lead to
- If it works, this could point toward a new way to treat liver metastases by combining electric fields with standard drugs to better control tumor growth.
- What could go wrong
- This is a very early phase I trial with only 38 people, so it is mainly checking safety and side effects. It may not show clear benefit, and the device plus drugs could cause unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can delivering cancer drug directly to the liver shrink tumors?
- Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a Two-Drug combo outsmart resistant colorectal cancer?
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a Triple-Drug rechallenge tame colorectal cancer?